

The Cigna Group Investor Presentation

January 30, 2025

Forward-looking statements

CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected outlook for 2025 (including adjusted revenues; adjusted income from operations, including on a per share, and segment basis; adjusted SG&A expense ratio; adjusted effective tax rate; cash flow from operations; capital expenditures; shareholder dividends; weight average shares outstanding; medical care ratio; and total medical customers); future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational initiatives, including our ability to successfully implement actions across our business to strengthen our platform and build a more sustainable model for healthcare; economic, regulatory or competitive environments; capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payers, physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations which could lead to an impairment charge; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; our ability to attract, develop, retain and manage the succession of key employees and executives; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

Non-GAAP measures and other key financial information

Throughout this presentation, the term “adjusted earnings” means adjusted income (loss) from operations, and “adjusted earnings per share” or “adjusted EPS” means adjusted income (loss) from operations on a diluted per share basis.

Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the underlying results of operations of the Company’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income (loss). Adjusted income (loss) from operations is defined as shareholders’ net income (loss) (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income (loss).

Adjusted revenues is used by The Cigna Group’s management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. For the twelve months ended December 31, 2024, special items reflects an impairment of dividend receivable for VillageMD accrued dividends of \$182.0 million. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues.

Note Regarding Outlook

The Company’s long-term outlooks include future share repurchases and anticipated dividends, but does not include the potential effects from other business combinations or divestitures that may occur after the date of this presentation. The Company’s outlook for 2025 assumes that the previously announced divestiture of the Company’s Medicare businesses will close in the first quarter of 2025.

Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income (including on a per share basis) on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond our control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.

Note Regarding Share Repurchases and Dividends

The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.

The Cigna Group currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board’s determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company’s financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.

**Our purpose
and mission**




**To improve the
health and vitality
of those we serve**

Two high-performing growth platforms



Cross-enterprise leverage is mutually beneficial.

A decade of growth exceeding expectations



Long-term average annual adjusted earnings growth outlook

SPECIALTY AND CARE SERVICES

~30% OF EARNINGS
8–12% GROWTH

PHARMACY BENEFIT SERVICES


~30% OF EARNINGS
2–4% GROWTH



CIGNA HEALTHCARE

~40% OF EARNINGS
7–10% GROWTH

**Capital
deployment:
4–5%**
EPS growth



~20–25%
CAPITAL EXPENDITURES
AND SURPLUS TO
FUND GROWTH

~15%
DIVIDEND

~60–65%
STRATEGIC M&A,
SHARE REPURCHASE,
REPAY DEBT

Strong long-term shareholder value

LONG-TERM AVERAGE ANNUAL
ADJUSTED INCOME GROWTH

6–9%

+

LONG-TERM AVERAGE
ANNUAL CONTRIBUTION
FROM CAPITAL DEPLOYMENT

4–5%

ENTERPRISE

10–14%

long-term average annual adjusted EPS growth outlook

PLUS AN ATTRACTIVE DIVIDEND

1–2%

4Q24 results – Consolidated

(Dollars in millions, except where noted and per-share amounts)

	4Q24	4Q23	Change
Adjusted revenues			
Adjusted revenues ⁽¹⁾	\$65,683	\$51,149	28%
Adjusted income (loss) from operations			
Evernorth Health Services, pre-tax	\$2,146	\$1,890	14%
Cigna Healthcare, pre-tax	\$511	\$969	(47)%
Corporate and other operations, pre-tax	(\$424)	(\$400)	6%
Consolidated, after-tax ⁽¹⁾	\$1,845	\$1,999	(8)%
Weighted average shares outstanding	277.8M	294.6M	(6)%
Adjusted EPS ⁽¹⁾	\$6.64	\$6.79	(2)%
Key ratios and metrics			
Adjusted SG&A expense ratio ⁽¹⁾	5.7%	7.4%	(170) bps
Cash flow from operations	\$5,212	\$1,467	255%

(1) See the Appendix for a reconciliation of adjusted EPS, consolidated adjusted income (loss) from operations, adjusted revenues and adjusted SG&A expense ratio to diluted EPS, shareholders' net income, total revenues, and SG&A expense ratio, respectively.

FY24 results – Consolidated

(Dollars in millions, except where noted and per-share amounts)

	FY24	FY23	Change
Adjusted revenues			
Adjusted revenues ⁽¹⁾	\$247,099	\$195,322	27%
Adjusted income (loss) from operations			
Evernorth Health Services, pre-tax	\$7,001	\$6,442	9%
Cigna Healthcare, pre-tax	\$4,229	\$4,478	(6)%
Corporate and other operations, pre-tax	(\$1,697)	(\$1,602)	6%
Consolidated, after-tax ⁽¹⁾	\$7,741	\$7,448	4%
Weighted average shares outstanding	283.2M	296.9M	(5)%
Adjusted EPS ⁽¹⁾	\$27.33	\$25.09	9%
Key ratios and metrics			
Adjusted SG&A expense ratio ⁽¹⁾	5.9%	7.3%	(140) bps
Cash flow from operations	\$10,363	\$11,813	(12)%

(1) See the Appendix for a reconciliation of adjusted EPS, consolidated adjusted income (loss) from operations, adjusted revenues and adjusted SG&A expense ratio to diluted EPS, shareholders' net income, total revenues, and SG&A expense ratio, respectively.

4Q24 results – Evernorth Health Services

(Dollars in millions, except where noted)

	4Q24	4Q23	Change
Adjusted revenues			
Pharmacy Benefit Services	\$30,273	\$20,553	47%
Specialty and Care Services	\$23,471	\$19,966	18%
Total adjusted revenues	\$53,744	\$40,519	33%
Adjusted income from operations, pre-tax			
Pharmacy Benefit Services	\$1,198	\$1,146	5%
Specialty and Care Services	\$948	\$744	27%
Total adjusted income from operations, pre-tax	\$2,146	\$1,890	14%
Key ratios and metrics			
Pharmacy Benefit Services	4.0%	5.6%	(160) bps
Specialty and Care Services	4.0%	3.7%	30 bps
Total margin, pre-tax	4.0%	4.7%	(70) bps
SG&A expense ratio	1.8%	2.2%	(40) bps

FY24 results – Evernorth Health Services

(Dollars in millions, except where noted)

	FY24	FY23	Change
Adjusted revenues			
Pharmacy Benefit Services	\$111,822	\$76,792	46%
Specialty and Care Services	\$90,333	\$76,707	18%
Total adjusted revenues	\$202,155	\$153,499	32%
Adjusted income from operations, pre-tax			
Pharmacy Benefit Services	\$3,577	\$3,469	3%
Specialty and Care Services	\$3,424	\$2,973	15%
Total adjusted income from operations, pre-tax	\$7,001	\$6,442	9%
Key ratios and metrics			
Pharmacy Benefit Services	3.2%	4.5%	(130) bps
Specialty and Care Services	3.8%	3.9%	(10) bps
Total margin, pre-tax	3.5%	4.2%	(70) bps
SG&A expense ratio	1.9%	2.2%	(30) bps

4Q24 results – Cigna Healthcare

(Dollars in millions, except where noted)

	4Q24	4Q23	Change
Adjusted revenues			
Total adjusted revenues	\$13,331	\$13,005	3%
Adjusted income from operations, pre-tax			
Total adjusted income from operations, pre-tax	\$511	\$969	(47)%
Key ratios			
Total margin, pre-tax	3.8%	7.5%	(370) bps
Medical care ratio	87.9%	82.2%	570 bps
SG&A expense ratio	21.1%	22.4%	(130) bps
Medical customers (lives in thousands)			
U.S. Healthcare administrative services only (ASO)	13,649	13,890	(2)%
U.S. Healthcare insured	3,853	4,280	(10)%
International Health	1,645	1,610	2%
Total medical customers	19,147	19,780	(3)%

FY24 results – Cigna Healthcare

(Dollars in millions, except where noted)

	FY24	FY23	Change
Adjusted revenues			
Total adjusted revenues	\$52,914	\$51,205	3%
Adjusted income from operations, pre-tax			
Total adjusted income from operations, pre-tax	\$4,229	\$4,478	(6)%
Key ratios			
Total margin, pre-tax	8.0%	8.7%	(70) bps
Medical care ratio	83.2%	81.3%	190 bps
SG&A expense ratio	20.4%	21.6%	(120) bps
Medical customers (lives in thousands)			
U.S. Healthcare administrative services only (ASO)	13,649	13,890	(2)%
U.S. Healthcare insured	3,853	4,280	(10)%
International Health	1,645	1,610	2%
Total medical customers	19,147	19,780	(3)%

FY2025 guidance

(Dollars in millions, except where noted and per-share amounts)

2025 Guidance

Adjusted revenue

Adjusted revenues	at least \$252,000
-------------------	--------------------

Adjusted income from operations

Consolidated, after-tax	at least \$7,900
-------------------------	------------------

Evernorth Health Services, pre-tax	at least \$7,200
------------------------------------	------------------

Cigna Healthcare, pre-tax	at least \$4,100
---------------------------	------------------

Adjusted EPS	at least \$29.50
--------------	------------------

Key ratios and metrics

Medical care ratio	83.2% to 84.2%
--------------------	----------------

Adjusted SG&A expense ratio	~5.4%
-----------------------------	-------

Adjusted effective tax rate	~19.0%
-----------------------------	--------

Cash flow from operations	~\$10,000
---------------------------	-----------

Capital Expenditures	~\$1,400
----------------------	----------

Shareholder Dividends	~\$1,600
-----------------------	----------

Total medical customers	~18.1M
-------------------------	--------

Weighted average shares outstanding	266 to 270
-------------------------------------	------------

Appendix

Definitions of key financial and business terms

Medical care ratio represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through guaranteed cost or experience-rated funding arrangements.

SG&A expense ratio on a GAAP basis for the fourth quarter 2024 represents enterprise selling, general and administrative expenses of \$3,865 million as a percentage of total revenue of \$65.6 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the fourth quarter 2023 represents enterprise selling, general and administrative expenses of \$4,062 million as a percentage of total revenue of \$51.1 billion at a consolidated level.

SG&A expense ratio on a GAAP basis for the full year 2024 represents enterprise selling, general and administrative expenses of \$14,844 million as a percentage of total revenue of \$247.1 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the full year 2023 represents enterprise selling, general and administrative expenses of \$14,822 million as a percentage of total revenue of \$195.3 billion at a consolidated level.

Adjusted SG&A expense ratio for the fourth quarter 2024 represents enterprise selling, general and administrative expenses of \$3,767 million excluding special items of \$98 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the fourth quarter 2023 represents enterprise selling, general and administrative expenses of \$3,785 million excluding special items of \$277 million as a percentage of adjusted revenue at a consolidated level.

Adjusted SG&A expense ratio for the full year 2024 represents enterprise selling, general and administrative expenses of \$14,569 million excluding special items of \$275 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the full year 2023 represents enterprise selling, general and administrative expenses of \$14,324 million excluding special items of \$498 million as a percentage of adjusted revenue at a consolidated level.

Adjusted effective tax rate is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, "consolidated effective tax rate". We define adjusted effective tax rate as the consolidated income tax rate applicable to the Company's pre-tax income excluding pre-tax income attributable to noncontrolling interests, net investment results, amortization of acquired intangible assets, and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Management is not able to provide a reconciliation to the consolidated effective tax rate on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items.

Total medical customers includes individuals who meet any one of the following criteria: are covered under a medical insurance policy, managed care arrangement, or service agreement issued by Cigna Healthcare; have access to Cigna Healthcare's provider network for covered services under their medical plan; or have medical claims that are administered by Cigna Healthcare.

Reconciliation of GAAP to non-GAAP financial measures

Shareholders' net income and diluted earnings per share

Three Months Ended December 31, 2024	Dollars in millions		Diluted earnings per share	
	Pre-Tax	After-Tax	Pre-Tax	After-Tax
Shareholders' net income		\$1,424		\$5.13
Adjustments to reconcile to adjusted income from operations:				
Net investment (gains) ⁽¹⁾	(\$34)	(\$18)	(\$0.12)	(\$0.06)
Amortization of acquired intangible assets	\$424	\$375	\$1.53	\$1.34
Special items				
Integration and transaction-related costs	\$98	\$76	\$0.35	\$0.27
Net (gains) on sale of businesses	(\$130)	(\$21)	(\$0.47)	(\$0.07)
Deferred tax expenses, net		\$9		\$0.03
Adjusted income from operations		\$1,845		\$6.64



(1) Includes Net investment losses/gains as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Reconciliation of GAAP to non-GAAP financial measures

Shareholders' net income and diluted earnings per share

Year Ended December 31, 2024	Dollars in millions		Diluted earnings per share	
	Pre-Tax	After-Tax	Pre-Tax	After-Tax
Shareholders' net income		\$3,434		\$12.12
Adjustments to reconcile to adjusted income from operations:				
Net investment losses ⁽¹⁾	\$2,533	\$2,529	\$8.95	\$8.93
Amortization of acquired intangible assets	\$1,703	\$1,347	\$6.01	\$4.76
Special items				
Integration and transaction-related costs	\$275	\$211	\$0.97	\$0.75
Impairment of dividend receivable	\$182	\$138	\$0.64	\$0.49
Net (gains) on sale of businesses	(\$24)	(\$2)	(\$0.08)	(\$0.02)
Deferred tax expenses, net		\$84		\$0.30
Adjusted income from operations		\$7,741		\$27.33



(1) Includes Net investment losses/gains as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Reconciliation of GAAP to non-GAAP financial measures

Shareholders' net income and diluted earnings per share

Three Months Ended December 31, 2023	Dollars in millions		Diluted earnings per share	
	Pre-Tax	After-Tax	Pre-Tax	After-Tax
Shareholders' net income		\$1,029		\$3.49
Adjustments to reconcile to adjusted income from operations:				
Net investment losses ⁽¹⁾	\$69	\$58	\$0.23	\$0.20
Amortization of acquired intangible assets	\$451	\$360	\$1.53	\$1.22
Special items				
Integration and transaction-related costs	\$25	\$20	\$0.08	\$0.07
Loss on sale of businesses	\$1,478	\$1,410	\$5.02	\$4.79
Charge for organizational efficiency plan	\$252	\$193	\$0.86	\$0.66
Deferred tax (benefits), net		(\$1,071)		(\$3.64)
Adjusted income from operations		\$1,999		\$6.79



(1) Includes Net investment losses/gains as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Reconciliation of GAAP to non-GAAP financial measures

Shareholders' net income and diluted earnings per share

Year Ended December 31, 2023	Dollars in millions		Diluted earnings per share	
	Pre-Tax	After-Tax	Pre-Tax	After-Tax
Shareholders' net income		\$5,164		\$17.39
Adjustments to reconcile to adjusted income from operations:				
Net investment losses ⁽¹⁾	\$135	\$114	\$0.45	\$0.38
Amortization of acquired intangible assets	\$1,819	\$1,413	\$6.13	\$4.77
Special items				
Integration and transaction-related costs	\$45	\$35	\$0.15	\$0.12
Loss on sale of businesses	\$1,499	\$1,429	\$5.05	\$4.81
Charge for organizational efficiency plan	\$252	\$193	\$0.85	\$0.65
Charge associated with litigation matters	201	171	\$0.68	\$0.58
Deferred tax (benefits), net		(\$1,071)		(\$3.61)
Adjusted income from operations		\$7,448		\$25.09



(1) Includes Net investment losses/gains as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Reconciliation of GAAP to non-GAAP financial measures

Adjusted Revenues

Three Months Ended December 31	2024	2023
Total Revenues	\$65,649	\$51,114
Net investment results from certain equity method investments	\$34	\$35
Adjusted Revenues	\$65,683	\$51,149

Three Months Ended December 31	2024	2023
Adjusted Revenues by Segment		
Evernorth Health Services	\$53,744	\$40,519
Cigna Healthcare	\$13,331	\$13,005
Corporate & Other Operations	(\$1,392)	(\$2,375)
Adjusted Revenues	\$65,683	\$51,149

Reconciliation of GAAP to non-GAAP financial measures

Adjusted Revenues

Year Ended December 31	2024	2023
Total Revenues	\$247,121	\$195,265
Net investment results from certain equity method investments	(\$204)	\$57
Special item related to impairment of dividend receivable	\$182	
Adjusted Revenues	\$247,099	\$195,322

Year Ended December 31	2024	2023
Adjusted Revenues by Segment		
Evernorth Health Services	\$202,155	\$153,499
Cigna Healthcare	\$52,914	\$51,205
Corporate & Other Operations	(\$7,970)	(\$9,382)
Adjusted Revenues	\$247,099	\$195,322

Reconciliation of GAAP to non-GAAP financial measures

Shareholders' net income and diluted earnings per share

Year Ended December 31	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Shareholders' net income	\$12.12	\$17.39	\$21.41	\$15.75	\$22.96	\$13.44	\$10.54	\$8.77	\$7.19	\$8.04	\$7.83
Adjustments to reconcile to adjusted income from operations:											
Net investment losses (gains) ⁽¹⁾	\$8.93	\$0.38	\$1.59	(\$0.47)	(\$0.66)	(\$0.50)	(\$0.42)	(\$0.61)	(\$0.42)	(\$0.15)	(\$0.40)
Amortization of acquired intangible assets, net	\$4.76	\$4.77	\$4.30	\$4.38	\$3.88	\$5.92	\$0.71	\$0.26	\$0.36	\$0.30	\$0.44
Adjustment for transitioning clients	\$ -	\$ -	\$ -	\$ -	\$ -	(\$3.46)	(\$0.19)	\$ -	\$ -	\$ -	\$ -
Special items	\$1.52	\$2.55	(\$3.94)	\$0.82	(\$7.73)	\$1.65	\$2.74	\$2.04	\$0.97	\$0.47	\$ -
Adjusted income from operations	\$27.33	\$25.09	\$23.36	\$20.48	\$18.45	\$17.05	\$14.22	\$10.46	\$8.10	\$8.66	\$7.87



(1) Includes Net investment losses/gains as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.